

NKURE THERAPEUTICS PRIVATE LIMITED
CIN : U73100KA2022PTC157838
Balance Sheet as at 31st March 2023

(Amount in '000)

Particulars	Note	As at 31st March, 2023
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share Capital	3	12,900.00
Reserves & Surplus	4	(12,917.96)
		(17.96)
Non-Current Liabilities		
Long Term Borrowings	5	12,500.00
		12,500.00
Current Liabilities		
Trade Payables	6	
Due to micro and small enterprises		44.00
Due to others		649.59
Other Current Liabilities	7	16,159.01
		16,852.60
TOTAL		29,334.64
ASSETS		
Non Current Assets		
Long term Loans and Advances	8	465.83
		465.83
Current Assets		
Cash and Cash Equivalents	9	27,245.17
Short-term Loans and Advances	10	1,623.64
		28,868.81
TOTAL		29,334.64

The accompanying notes forming part of the financial statements

In terms of our report attached

For and on behalf of the board of directors

For, Dhirubhai Shah & Co LLP
Chartered Accountants
FRN: 102511W/W100298

Anik S Shah
Partner
M.No: 140594

Ashok Nana Vohra
Director
DIN : 01186182

Mahendra Rao
Director
DIN : 07580629

Place : Ahmedabad
Date : 04/09/2023

Place : Bangalore
Date : 04/09/2023

NKURE THERAPEUTICS PRIVATE LIMITED

CIN : U73100KA2022PTC157838

Statement of Profit and Loss for the period 11th February, 2022 to 31st March, 2023

(Amount in '000)

Particulars	Note No.	For the period 11th February, 2022 to 31st March, 2023
1 Revenue		
Revenue From Operations		-
2 Other Income		-
3 Total Income	(1 + 2)	-
4 Expenses		
Employee Benefits Expense	11	860.33
Other Expenses	12	12,057.63
Total Expenses		12,917.96
5 Profit/(Loss) Before Tax	(3-4)	(12,917.96)
6 Tax Expense:		
Current Tax		-
Deferred Tax		-
7 Profit /(Loss) for the year	(5-6)	(12,917.96)
Earnings Per Share (Face Value Rs. 10 Per Share)	17	
Basic EPS		(10.01)
Diluted EPS		(7.78)

See accompanying notes forming part of the financial statements

In terms of our report attached

For and on behalf of the board of directors

For, Dhirubhai Shah & Co LLP
Chartered Accountants
FRN: 102511W/W100298

Anik S Shah
Partner
M.No: 140594

Ashok Nana Vohra
Director
DIN : 01186182

Mahendra Rao
Director
DIN : 07580629

Place : Ahmedabad
Date : 04/09/2023

Place : Bangalore
Date : 04/09/2023

NKURE THERAPEUTICS PRIVATE LIMITED

CIN : U73100KA2022PTC157838

Notes to the financial statements for the period ended 31st March, 2023

1 Corporate information

The Company is a Private Limited Company, incorporated on 11th February, 2022 under the Companies Act, 2013. The Company is principally engaged to undertake research in using cells and their derivatives to generate therapeutic products to treat cancer and cancer related pathology.

Company has not started commercial activities as this is first year of a Company Incorporation.

2 Significant accounting policies :

a. Basis of Preparation of Financial Statements

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Accounting Standards) Rules, 2021, as amended ("Accounting Standards") and the relevant provisions of the Companies Act, 2013 ("the 2013 Act"). The financials statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year, unless otherwise stated.

b. Use of Estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the period. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

c. Property Plant & Equipment

Tangible Assets

There is no tangible assets as on balance sheet date.

Intangible Assets

There is no intangible assets as on balance sheet date.

d. Revenue recognition

There is no revenue for current year.

e. Taxes on Income

Provision for current tax is made on the basis of annual taxable income for the current accounting period & in accordance with the provisions of the Income Tax Act, 1961.

f. Provisions, contingent liabilities and contingent assets

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the enterprise are disclosed as contingent liability and not provided for. Such liability is not disclosed if the possibility of outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements.

NKURE THERAPEUTICS PRIVATE LIMITED

CIN : U73100KA2022PTC157838

Notes to the financial statements for the period ended 31st March, 2023

g. Earnings Per Share

Basic earnings per share is computed by dividing the profit/(loss) after tax by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit/(loss) after tax as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the year, unless they have been issued at a later date.

(Amount in '000)

3 Equity Share Capital

Particulars	As at 31st March 2023
Authorised Share Capital 20,00,000 equity shares of Rs. 10 each	20,000.00
	20,000.00
Issued, Subscribed and fully paid-up equity shares with voting rights 12,90,000 equity shares of Rs. 10 each	12,900.00
	12,900.00

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Equity Shares

Particulars	As at 31st March 2023	
	No. Shares	Amount
At the beginning of the period	-	-
Issued during the period	12,90,000	12,900.00
Outstanding at the end of the year	12,90,000	12,900.00

b. Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to vote per share.

c. Details of shareholders holding more than 5% shares in the Company

Particulars	As at 31st March 2023	
	No. Shares	%
Ashok Vohra	2,06,000	15.97%
Ferzaan Engineer	2,06,000	15.97%
Jogin Desai	2,06,000	15.97%
Suresh Ramu	2,06,000	15.97%
Amit Sharma	74,000	5.74%
Rajarshi Pal	68,000	5.27%
Mahendra Rao	3,24,000	25.12%
	12,90,000	100.00%

d. Shares held by Promoters at the end of the year 31st March, 2023

Name of Promotor	Class of Shares	No. of Shares	% of Total Shares	% Change during the year
Ashok Vohra	Equity	2,06,000	15.97%	0.00%
Alka Vohra (*)	Equity	-	0.00%	100.00%

(*) At the time of incorporation Ms. Alka Vohra has subscribed for 10,000 shares which were transferred to Dr. Mahendra Rao on 27.03.2022.

4 Reserves and Surplus

Particulars	As at 31st March 2023
Surplus in the Statement of Profit and Loss	
Opening Balance	-
Profit /(Loss) for the period	(12,917.96)
Total Reserve & Surplus	(12,917.96)

5 Long Term Borrowings

Particulars	As at 31st March 2023
Unsecured	
Compulsorily Convertible Debenture	12,500.00
	12,500.00

Note:

12,50,000 compulsorily convertible debentures (CCD's) face value of Rs. 10/- each issued on 19th December, 2022 and 3rd February, 2023. The company shall mandatorily convert the CCD's into equity shares on the CCD maturity date. The same will be converted as per various CCD Agreements.

(Amount in '000)

6 Trade Payables

Particulars	As at 31st March 2023
Trade Payables	
Due to Micro and small enterprises	44.00
Due to others	649.59
	<u>693.59</u>

6.1 Trade Payable ageing schedule as at 31 March 2023

Particulars	Outstanding for following periods from date of transaction					Total
	Unbilled	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	-	44.00	-	-	-	44.00
Others	-	649.59	-	-	-	649.59
Disputed dues- MSME	-	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-	-
Total	-	693.59	-	-	-	693.59

Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006)

Micro and small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006) have been determined based on the information available with the Company and the required disclosures are given below:

	As at 31st March 2023
(a) Principal amount remaining unpaid	44.00
(b) Interest due thereon	-
(c) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-
(d) The amount of interest due and payable for the year (where the principal has been paid but interest under the MSMED Act, 2006 not paid)	-
(e) The amount of interest accrued and remaining unpaid	-
(f) The amount of further interest due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23.	-

7 Other Current Liabilities

Particulars	As at 31st March 2023
Statutory liabilities	524.71
Salary Payable	108.10
Provision for expenses	26.20
Other Short Term Fund *	15,500.00
	<u>16,159.01</u>

* Received Rs. 15,500 thousand towards application money for 15,50,500 compulsorily convertible debentures (CCD's) face value of Rs. 10/- each for which allotment is pending as on balance sheet date.

8 Long Term Loans & Advances

Particulars	As at 31st March 2023
Unsecured, considered good	
Security deposits	465.83
	<u>465.83</u>

9 Cash and Cash Equivalents

Particulars	As at 31st March 2023
Balances with banks (*)	
In current accounts	27,245.17
Cash on hand	-
	<u>27,245.17</u>

* Current account balance includes Rs. 15,500 thousand towards application money for 15,50,500 compulsorily convertible debentures (CCD's) face value of Rs. 10/- each for which allotment is pending as on balance sheet date.

10 Short Term Loans & Advances

Particulars	As at 31st March 2023
Unsecured, considered good	
Balances with government authorities	1,623.64
	<u>1,623.64</u>

(Amount in '000)

11 Employee Benefit Expenses

Particulars	For the period 11th February, 2022 to 31st March, 2023
Salaries, wages and allowances	807.81
Staff Welfare Expense	52.52
	860.33

12 Other Expenses

Particulars	For the period 11th February, 2022 to 31st March, 2023
Research Expense (Refer Note 13)	11,038.15
Incorporation Expenses	306.65
Legal and Professional	414.07
Foreign Exchange Fluctuation Loss	82.31
Rent	15.00
Statutory auditors remuneration (Refer Note 14)	25.00
Bank Charges	8.45
Office Expenses	89.16
Travelling & Conveyance	62.18
Communication expenses	8.86
Stamp Duty Expense	4.69
Miscellaneous expenses	3.12
	12,057.63

13 Research Expense

Particulars	For the period 11th February, 2022 to 31st March, 2023
Research Consultancy	2,970.58
Laboratory Rent (Usage) Charges	1,088.58
Reagent Expense	2,537.06
License Fees	4,435.25
Custom Duty	6.69
	11,038.15

14 Statutory Auditor's Remuneration

Particulars	For the period 11th February, 2022 to 31st March, 2023
Statutory Audit fees	25.00
	25.00

15 Contingent liabilities and Commitments, (to the extent, not provided for) - NIL
Estimated amount of contract remaining to be executed on Capital Account - NIL

16 Related party disclosures as required by Accounting Standard – 18 issued by the Institute of Chartered Accountants of India:-

a. Names of related parties & description of relationship :

Nature of Relationship	Name of Related Parties
Key management personnel	Ashok Nana Vohra, Director Alka Vohra, Director (Resigned on 04/03/2022) Mahendra Rao, Director (w.e.f. 04/03/2022)

b. Transaction with related parties

Related Party	Nature of Transaction	For the period 11th February, 2022 to 31st March, 2023
Ashok Nana Vohra	Loan taken	703.12
Ashok Nana Vohra	Repayment of Loan	703.12
Ashok Nana Vohra	Reimbursement of expenses	83.68
Alka Vohra	Reimbursement of expenses	63.71
Dr. Mahendra Rao	Professional Fees	1,153.01

c. Balances with related parties

Related Party	Nature of Balance	As at 31st March 2023
Ashok Nana Vohra	Reimbursement of expense payable	62.18

17 Pursuant to the Accounting Standard (AS- 20) – Earnings per Share, the disclosure is as under:

Particulars	For the period 11th February, 2022 to 31st March, 2023	
Basic and Diluted EPS		
Net Profit/(Loss) after tax as per Statement of Profit and Loss attributable to shareholders	Amt in '000	(12,918)
Weighted average number of equity shares outstanding during the period for basic EPS	Nos.	12,90,000
Weighted average number of potential dilutive equity shares for diluted EPS (*)	Nos.	3,70,851
Nominal Value of equity share	Rs.	10
Basic Earnings Per Share	Rs.	(10.01)
Diluted Earnings Per Share	Rs.	(7.78)

(*) Pursuant to the conditions set forth in the CCD Agreement, it has been worked out based on the assumptions that as on the balance sheet date, the computed conversion rate for Compulsory Convertible Debentures into equity shares stands at 3,70,851 equity shares.

18 Earnings in Foreign Currencies - NIL

19 Expenditure made in Foreign Currencies

Particulars	For the period 11th February, 2022 to 31st March, 2023
Subscription Charges	4,435.25
Research Expense	513.30

20 Company is operating only in single segment so segment reporting is not applicable.

21 Key Ratios

Comparative ratios are not provided since this is first year since incorporation.

22 Additional Discloser As Per New Schedule iii Requirements :

- A. The Company has no Property, Plant and Equipment reported in this Financial Statements hence reporting is Not Applicable.
 B. There have been no proceedings initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
 C. There is no borrowing from Bank in the company.
 D. As per the internal assessment of the Management, the Company does not have any transactions with companies struck off.
 E. There no charges or satisfaction of charges yet to be registered with Registrar of Companies beyond the statutory period.
 F. There are no undisclosed income surrendered or disclosed as income during the period / year in the tax assessment under the Income Tax Act, 1961.
 G. The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (intermediaries) with the understanding tht the intermediary Shall:
 (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 (b) provide any gurantee, seurity or the like to or on behalf of the Ultimate Beneficiaries.
 H. The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recored in writing or otherwise) that the Company shall:
 (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 (b) provide any gurantee, seurity or the like to or on behalf of the Ultimate Beneficiaries.
 I. The Company is not declared as willful defaluter by any bank or Financial Institution as on the Balance Sheet.
 J. During the year, the Company has not traded or invested in Crypto Currency or Virtual Currency.

23 As per Section 2(41) of the Companies Act, 2013, financial statements have been prepared for a period commencing from 11th February, 2022 to 31st March, 2023 being first financial year of the company and accordingly no previous year's figures have been published as this being the first year of the company.

Signature to Notes 1 to 23

In terms of our report attached

For and on behalf of the board of directors

For, Dhirubhai Shah & Co LLP
 Chartered Accountants
 FRN: 102511W/W100298

Anik S Shah
 Partner
 M.No: 140594

Ashok Nana Vohra
 Director
 DIN : 01186182

Mahendra Rao
 Director
 DIN : 07580629

Place : Ahmedabad
 Date : 04/09/2023

Place : Bangalore
 Date : 04/09/2023